Clay Or Zeolite Containing Patents (Class 424/9.31)
-
Patent number: 11284622Abstract: Compositions comprising Methylobacterium with anti-fungal activity, methods for controlling plant pathogenic fungi, and methods of making the compositions are provided.Type: GrantFiled: December 7, 2017Date of Patent: March 29, 2022Assignee: NewLeaf Symbiotics, Inc.Inventors: Renée A. Rioux, Charles Michael McFatrich, Kishore Nannapaneni
-
Patent number: 10500206Abstract: Provided is a composition for wound healing, which includes adenine and a pharmaceutically acceptable salt thereof. Also provided is a method for enhancing wound healing in a subject in need thereof including administering to the subject the composition.Type: GrantFiled: March 13, 2017Date of Patent: December 10, 2019Assignee: ENERGENESIS BIOMEDICAL CO., LTD.Inventors: Han-Min Chen, Cheng-Yi Kuo, Chun-Fang Huang, Jiun-Tsai Lin
-
Patent number: 8367038Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest arc inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.Type: GrantFiled: May 23, 2005Date of Patent: February 5, 2013Assignee: HMI Medical Innovations, LLCInventor: Gerard M. Housey
-
Patent number: 7749957Abstract: Combinatorially generated peptides are provided that have binding affinity for clay. The peptides may be used to deliver benefit agents to various clay surfaces.Type: GrantFiled: April 4, 2007Date of Patent: July 6, 2010Assignee: E.I. du Pont de Nemours and CompanyInventors: Steven Dale Ittel, Scott D. Cunningham, Pierre E. Rouviere, Stephen R. Fahnestock, John P. O'Brien, Eberhard Schneider, Gregor Schurmann, Peter Wagner
-
Publication number: 20100143251Abstract: The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus.Type: ApplicationFiled: February 17, 2010Publication date: June 10, 2010Inventors: Gilles D. Tamagnan, David Alagille, Herve Da Costa
-
Patent number: 7435380Abstract: A pseudo-plastic or thixotropic carrier having anti-malodorous components dissolved or suspended therein is sprayed on the internal surfaces of an ostomy bag or pouch. The viscoelastic properties of the carrier allow the composition to be conveniently dispensed from a spray bottle into the ostomy bag and retained on the inner walls thereof without being displaced therefrom by incoming waste during use of the ostomy bag. This allows the composition to continue to deodorize the ostomy bag headspace even after waste material begins to fill the bag.Type: GrantFiled: September 30, 2002Date of Patent: October 14, 2008Assignee: Church & Dwight Co., Inc.Inventor: Anthony E. Winston
-
Publication number: 20080206134Abstract: A radiographic composition for promoting the formation of clots in blood includes a zeolite and iodine. A device for promoting the clotting of blood at an internal wound site includes a catheter; a delivery instrument insertable through the catheter; a radioopaque blood clotting agent that deliverable through the delivery instrument; and a positive pressure apparatus that can dispense the blood clotting agent to the wound site through the delivery instrument. A system for radiographically imaging an internally bleeding wound includes means for delivering a radioopaque blood clotting agent and means for radiographically imaging the radioopaque blood clotting agent. A method of imaging an internally bleeding wound includes the steps of inserting a catheter into a patient; advancing the catheter to a point adjacent the bleeding wound; depositing a radioopaque zeolite at the bleeding wound; and imaging the radioopaque zeolite to monitor blood-clotting caused by the zeolite.Type: ApplicationFiled: February 22, 2007Publication date: August 28, 2008Inventors: Denny Lo, Giacomo Basadonna
-
Patent number: 7135198Abstract: A preparation for oral administration, in which plant material is comminuted and treated by mixing thoroughly with an extractant. After mixing, porous inorganic particles are added to the resulting suspension, thoroughly mixed with mixture and dried. The preparation provides a homogeneous distribution of the active ingredient as well as long stability and good bioavailability of the active ingredient.Type: GrantFiled: September 30, 2002Date of Patent: November 14, 2006Assignee: Bogar AGInventors: Marijkc Frater-Schroder, Georg Frater
-
Patent number: 6689377Abstract: The invention relates to a solid antimicrobial product suitable for the preservation of an organic material and for combating of detrimental microorganisms, as well as for pH control. The product contains, absorbed into a support a concentrated formic acid partly neutralized with gaseous ammonia, the water content of the formic acid being below 2% by weight. In addition, the invention comprises a method for preparing the product.Type: GrantFiled: October 23, 2002Date of Patent: February 10, 2004Assignee: Kemira Chemicals OyInventors: Eero Aitta, Jouko Arvola, Pekka Johnson, Juha Kangastalo, Marjo Luoma, Ilkka Pollari
-
Patent number: 6436366Abstract: Wound healing is impaired in many diabetics, who suffer increased risk of chronic foot ulceration and amputation. Diabetic patients with poor healing ability were found to possess significantly lower fasting urinary nitrate levels than diabetic patients with normal healing ability or non-diabetic controls, implicating decreased endogenous nitric oxide activity as the mediator of diabetes-impaired wound healing. Methods and kits are provided for predicting the wound healing ability of diabetic patients and patients with venous stasis ulceration or another disease or condition characterized by chronically impaired cutaneous wound healing in some patients based on the levels of nitric oxide related products such as nitrate or nitrite in urine or other specimens. Methods are also provided for treating non-wound healing patients and monitoring diabetic ulcer treatment.Type: GrantFiled: February 6, 2001Date of Patent: August 20, 2002Inventor: Joseph V. Boykin, Jr.
-
Publication number: 20010048915Abstract: Wound healing is impaired in many diabetics, who suffer increased risk of chronic foot ulceration and amputation. Diabetic patients with poor healing ability were found to possess significantly lower fasting urinary nitrate levels than diabetic patients with normal healing ability or non-diabetic controls, implicating decreased endogenous nitric oxide activity as the mediator of diabetes-impaired wound healing. Methods and kits are provided for predicting the wound healing ability of diabetic patients based on the levels of nitric oxide related products such as nitrate or nitrite in urine or other specimens. Methods are also provided for treating non-wound healing diabetics and monitoring diabetic ulcer treatment.Type: ApplicationFiled: June 21, 2001Publication date: December 6, 2001Inventor: Joseph Boykin
-
Patent number: 6312663Abstract: Wound healing is impaired in many diabetics, who suffer increased risk of chronic foot ulceration and amputation. Diabetic patients with poor healing ability were found to possess significantly lower fasting urinary nitrate levels than diabetic patients with normal healing ability or non-diabetic controls, implicating decreased endogenous nitric oxide activity as the mediator of diabetes-impaired wound healing. Methods and kits are provided for predicting the wound healing ability of diabetic patients based on the levels of nitric oxide related products such as nitrate or nitrite in urine or other specimens. Methods are also provided for treating non-wound healing diabetics and monitoring diabetic ulcer treatment.Type: GrantFiled: March 1, 2000Date of Patent: November 6, 2001Inventor: Joseph V. Boykin, Jr.